GEN Exclusives

More »

GEN News Highlights

More »
Sep 13, 2007

Celgene Plugs $20M into PTC Therapeutics

  • Celgene will make a $20 million equity investment in PTC Therapeutics. In return, Celgene will gain the right to enter an exclusive research deal related to two oncology targets for the development of small molecules with PTC’s GEMS (gene expression modulation by small molecules) technology.

    If Celgene exercises this option, PTC may receive funding for research efforts and milestone payments per target. Celgene will receive exclusive worldwide rights and pay PTC royalties on net sales of any products.

    The GEMS platform identifies small molecules that modulate post-transcriptional control mechanisms. These compounds target processes that act through the untranslated regions of mRNA.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Stopping Research Fraud

What is the best approach to curbing scientific misconduct and outright fraud?